Drugs / BCD-261
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07535775 | May → Oct 2026 expected | — | SPH-BIOCAD (HK) Limited | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06715540 | Mar 2024 → Feb 2025 overdue | — | Biocad | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07078994 | Aug 2025 → May 2027 expected | Crohn disease | Biocad | Recruiting | No outcome recorded |
| Phase 2 | NCT07080034 | Aug 2025 → Jan 2027 expected | ulcerative colitis | Biocad | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Biocad | Regulatory Инновационную разработку BIOCAD для терапии болезни Крона и язвенного колита изучают в России и Китае biocad.ru ↗
BIOCAD получил одобрение регуляторных органов Китая на проведение клинического исследования первой фазы BCD-261 с участием здоровых добровольцев. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Biocad | Инновационную разработку BIOCAD для терапии болезни Крона и язвенного колита изучают в России и Китае biocad.ru ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-261 | “study drug (BCD-261)” NCT07080034 ↗ |
| Modality | Monoclonal antibody | “Anti-TL1A human monoclonal antibody” NCT06715540 ↗ |
| Route | Subcutaneous | “Solution for Subcutaneous Injection in vials” NCT06715540 ↗ |